Irreversible electroporation, or IRE, is not a new idea. The technique uses high-voltage, low-energy electrical pulses delivered between thin needle electrodes to punch permanent nanoscale pores into cell membranes. Once membrane integrity is irreversibly lost, cells die through apoptotic and necrotic pathways rather than through the heat-driven protein denaturation that characterizes radiofrequency or laser ablation. Because tissue destruction is electrical rather than thermal, the scaffolding of the tissue—the extracellular matrix, blood vessels, and nerves—largely survives. That property has made IRE attractive for treating tumors in organs such as the liver, pancreas, and prostate, where preserving surrounding structures matters enormously.

Conventional IRE, however, has an uncomfortable side effect. The unipolar pulses it employs are strong enough to stimulate nerves and muscles, producing dramatic whole-body contractions that typically require deep anesthesia and neuromuscular blockade. High-frequency irreversible electroporation, known as H-FIRE, addressed this by delivering ultra-short bipolar pulses that fall within the refractory period of nerve cells, keeping stimulation below the threshold for action potentials. Preclinical and early clinical studies of H-FIRE in prostate ablation have confirmed effective lesion formation with markedly reduced muscle contraction. But most of these studies relied on fixed waveform structures or single pulse widths, leaving open whether a smarter pulse recipe could do better.

The team behind the new work, based at Shanghai Municipal Hospital of Traditional Chinese Medicine and Shanghai Nortion Medical Technology, developed a device that generates what they call highly heavy-frequency bipolar compound steep pulses. Their hypothesis was simple but consequential: if pulses of different durations and field strengths interact with tissue in complementary ways, combining them in a single ablation sequence should permeabilize a broader population of cells than any single waveform could. The device has passed registration testing at the Shanghai Testing and Inspection Institute for Medical Devices and is cleared for clinical trials, making this canine study a critical preclinical stepping stone.

The experiment was designed as a sequential, stepwise parameter optimization. Each of the twenty Beagles contributed two prostate lobes, giving forty treatment sites and reducing the number of animals required. In the first phase, escalating voltages established safe operating ranges: with 5-microsecond pulses, voltages up to 2500 volts produced muscle contractions graded at most as moderate, while 50-microsecond pulses remained acceptable up to 1500 volts. In the second phase, the researchers compared single-pulse and compound-pulse protocols head to head under identical electrode placement. The results were unambiguous. A 5-microsecond pulse at 1500 V/cm ablated 39.30 square millimeters of tissue; a 50-microsecond pulse at 1000 V/cm managed 64.44 square millimeters. The compound protocol—both pulses in sequence—carved out 307.27 square millimeters, roughly five to eight times the area of either single-pulse approach.

The third phase systematically varied electric-field strength, interelectrode spacing, and insertion depth. Mean ablation areas in the low-, medium-, and high-parameter groups were 39.74, 175.46, and 228.49 square millimeters, respectively. The medium and high groups both significantly outperformed the low group, but the difference between medium and high was not statistically significant. Crucially, the high-parameter group produced significantly greater muscle contraction than the medium group. The authors interpret this through the sigmoidal dose-response characteristic of electroporation: once the tissue-specific ablation threshold—estimated at roughly 1072 V/cm for canine prostate—is exceeded, pushing the field higher adds little therapeutic benefit but preferentially amplifies neuromuscular stimulation, since nerve and muscle excitation thresholds sit far below the ablation threshold.

Electrode geometry proved equally important. At spacings of 10, 14, and 18 millimeters, mean ablation areas were 83.93, 226.25, and 216.20 square millimeters. The 14-millimeter configuration delivered the largest lesion, and the researchers conclude that the practical spacing window lies between 14 and 18 millimeters rather than at a single optimum. Increasing insertion depth from 10 to 20 millimeters, by contrast, yielded only a modest gain—from 83.93 to 90.10 square millimeters—suggesting that cross-sectional lesion size is governed more by electrode spacing than by how deep the needles sit within the gland.

Safety findings were reassuring across the seven-day follow-up. No serious adverse events occurred, wounds healed without complication, and gross prostate appearance remained normal. Red blood cell counts, hemoglobin, and platelets showed no clinically relevant changes relative to published reference change values for laboratory Beagles. White blood cell counts rose transiently after the procedure, a pattern the authors attribute to surgical stress and the localized inflammatory response that follows tissue injury rather than systemic toxicity. Only one dog showed a leukocyte increase exceeding the reference change value, consistent with a more pronounced inflammatory reaction.

The mechanism behind the compound-pulse advantage remains an open question, though a plausible model has emerged from earlier work in potato tubers, rabbit liver, mouse tumors, and porcine liver. High-voltage narrow pulses can perforate cell membranes, but those perforations often reseal without killing the cell. A subsequent lower-voltage, broader pulse may widen these transient pores past the point of recovery, pushing cells into irreversible death. In effect, the two waveforms act as a one-two punch: the first creates the vulnerability, the second exploits it. The authors caution that this synergy was not directly tested in prostate tissue and that impedance measurements and computational field modeling will be needed to confirm it.

Limitations temper the enthusiasm appropriately. The study was conducted in healthy canine prostates, which may not fully mirror the electrical and tissue properties of human benign or malignant prostate disease. Each parameter configuration was evaluated in only three prostate lobes, and the reported field strengths represent device output settings rather than measured tissue distributions. Adjacent critical structures such as the urethra were preserved histologically but not systematically evaluated, and longer follow-up with electromyography will be needed to fully characterize neuromuscular responses. Still, the core conclusion stands: the medium-parameter compound protocol—5-microsecond pulses at 1500 V/cm combined with 50-microsecond pulses at 1000 V/cm—achieved a favorable balance between ablation area and muscle contraction, and no serious adverse events emerged. As the first systematic parameter optimization of compound steep-pulse ablation in a large-animal prostate model, the study lays the quantitative groundwork for the clinical trials that must follow before this technology reaches patients with benign prostatic hyperplasia or prostate cancer.

Subject of Research: Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety

Article Title: Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety

Article References: Chen, Z., Zhao, L., Zhang, Z., & Luo, Z. (2026). Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety. Frontiers in Urology, 6, Article 1721078. https://doi.org/10.3389/fruro.2026.1721078

Image Credits: AI Generated

DOI: 10.3389/fruro.2026.1721078

Keywords: Compound, steep-pulse, irreversible, electroporation, prostate, ablation, Beagle, dogs, parameter, evaluation, short-term, safety

The research team, led by Dayeon Kang and Jaemin Kim of Gyeongsang National University together with colleagues at the National Institute of Animal Science in Korea and the University of Rennes in France, focused on a deliberately clean experimental design. They studied clinically healthy beagle dogs divided into three distinct age groups, spanning adulthood from young adults to senior animals. Beagles were a strategic choice: as a genetically homogeneous single-breed population raised under controlled conditions, they minimize the confounding effects of breed, ancestry, and environment that plague most studies of aging in outbred populations, whether human or canine. That homogeneity means the molecular signals the team detected are more likely to reflect aging itself rather than background genetic variation.

The technical approach was comprehensive. The researchers performed whole-genome bisulfite sequencing, a method that converts unmethylated cytosines to uracils and thereby allows researchers to read the methylation status of individual CpG sites across the entire genome at base resolution. In parallel, they used RNA sequencing to quantify gene expression in the same animals, generating matched methylome and transcriptome profiles for each dog. DNA methylation, the attachment of methyl groups to cytosine bases at CpG dinucleotides, is a key epigenetic mark that helps determine whether genes are switched on or off, and its gradual alteration with age has become one of the most robust molecular signatures of aging across mammals.

The first major finding was one of stability with a twist. Global methylation levels, the overall fraction of methylated CpG sites across the genome, were highly conserved between individual dogs, even across age groups. The canine methylome, in other words, maintains its broad architecture throughout life. But when the team looked more closely, they found that variability, rather than average levels, was what changed. Both methylation variability and gene expression variability increased progressively as the dogs aged. This phenomenon, known as epigenetic drift, has been described in humans and mice, famously in studies showing that monozygotic twins diverge epigenetically over their lifetimes. The beagle data confirm that drift is not a quirk of laboratory rodents or of human populations exposed to decades of heterogeneous environments; it occurs even in genetically uniform dogs living under controlled conditions.

Crucially, the drift was not stochastic in the loose sense of being directionless. When the researchers examined where in the genome the increasing variability was concentrated, they found it was structured by genomic context. The relationship between CpG methylation and the expression of nearby genes weakened with age, indicating a gradual loss of epigenetic control over transcription. In a young animal, methylation at regulatory CpG sites acts as a reasonably reliable predictor of gene activity; in older animals, that coupling loosens. This decoupling suggests that aging erodes the precision of the regulatory machinery that links chemical marks on DNA to the output of the transcriptional apparatus, a finding that resonates with the broader view of aging as a progressive loss of molecular homeostasis and coordination.

Perhaps the most novel contribution of the study is its demonstration that methylation changes unfold in distinct, stage-specific patterns across the three age groups. Rather than a single uniform trajectory, the team identified early-shift patterns, in which methylation changes occur predominantly between the youngest and middle age groups; late-shift patterns, concentrated between the middle and oldest groups; and progressive patterns, in which changes accumulate steadily across the entire adult lifespan. These are not arbitrary categories. When the researchers performed pathway and gene-set enrichment analyses on the genes associated with each pattern, the groups showed partially overlapping but clearly distinct associations with established hallmarks of aging, the set of conserved biological processes, from genomic instability and telomere attrition to mitochondrial dysfunction and altered intercellular communication, that define mammalian aging.

This staging has important implications. It suggests that different biological programs of aging are switched on, or wind down, at different points of adulthood, and that a single snapshot late in life misses much of the story. It also aligns with recent work in other species. Studies in aging mice have documented nonlinear DNA methylation trajectories, and a 2024 analysis of human multi-omics profiles found that molecular markers of aging do not accumulate linearly but appear to cluster around specific windows, including midlife transitions. The beagle data extend that nonlinear picture to a large companion animal whose lifespan, roughly ten to fifteen years for many breeds, compresses the aging process into a timeframe researchers can actually study.

Dogs have become increasingly prominent in geroscience for exactly this reason. They share our environments, develop many of the same age-related diseases, including cancer, cardiac dysfunction, and cognitive decline, and their larger size and longer lifespan relative to mice make longitudinal studies more tractable in some respects. Previous work established epigenetic clocks for dogs and wolves, demonstrating that methylation-based age estimators translate remarkably well between dogs and humans, and the Dog Aging Project has been building large cohorts of companion dogs to study environmental and genetic determinants of healthy aging. What the new study adds is the integration layer: by pairing methylation with transcriptome data in the same individuals, it moves beyond cataloging age-associated marks to asking what those marks do to gene regulation.

The integrative design also matters for a persistent problem in epigenetic aging research: cellular heterogeneity. Blood, the tissue most commonly sampled in both human and canine studies, is a mixture of cell types whose proportions shift with age, and those shifts can masquerade as methylation changes. By examining methylation-expression relationships directly, the researchers could assess whether age-associated methylation changes actually correspond to altered gene output, providing a functional readout that pure methylation studies lack. The observed weakening of CpG-gene associations with age suggests that part of the methylation signal in older animals reflects genuine regulatory remodeling rather than mere compositional change, although the authors note that accounting for cellular composition remains critical in this field.

The practical payoff could be substantial. Understanding which methylation changes occur early versus late in adulthood could inform the development of better canine epigenetic clocks, ones that capture not just chronological age but biological stage, and could help veterinarians and researchers identify animals undergoing accelerated epigenetic aging before disease manifests. Given that dogs and humans share conserved methylation remodeling with age, the stage-specific patterns identified in beagles may also point to corresponding windows in human aging where interventions, whether dietary, pharmacological, or lifestyle-based, might be most effective. The raw data have been deposited in public repositories, with whole-genome bisulfite sequencing data under accession E-MTAB-15578 and RNA-seq data under E-MTAB-15574, making the resource available to the broader community. As companion dogs continue to emerge as premier models for translational aging research, this study provides both a methodological template and a conceptual map: aging, in dogs as in humans, is a choreographed sequence of regulatory changes, and knowing the choreography is the first step toward changing it.

Subject of Research: Integrative methylome and transcriptome profiling of age-associated epigenetic drift and regulatory remodeling in beagle dogs

Article Title: Integration of methylome and transcriptome reveals age-associated signatures of stage-specific dynamics and regulatory remodeling in dogs

Article References: Kang, D., Bok, E.-Y., Hong, C.-Y., Plassais, J., Choe, Y.-H., Lee, S.-L., & Kim, J. (2026). Integration of methylome and transcriptome reveals age-associated signatures of stage-specific dynamics and regulatory remodeling in dogs. GeroScience. https://doi.org/10.1007/s11357-026-02533-z

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02533-z

Keywords: DNA methylation, epigenetic drift, transcriptome, aging, dogs, beagle, GeroScience, epigenetic clock, gene expression, CpG sites, whole-genome bisulfite sequencing, Integration